ICAM1 and age-related macular degeneration: Izumi-Nagai et al. [30] found that the IL-6 receptor mediated activation of the signal transducer and activator of transcription-3 promotes CNV generation and the IL-6 receptor blockade could inhibit in vivo and in vitro expression of inflammation-related molecules such as monocyte chemotactic protein, intercellular adhesion molecule-1, VEGF, and macrophage infiltration, which then could be a therapeutic strategy to suppress CNV-associated AMD.